



Change in Leadership of SomnoMed

19th November 2018, SomnoMed (ASX:SOM) announced today that it had reached agreement with its Chief Executive Mr Derek Smith to step down from his position effective 16th November 2018. Mr Smith served as CEO of SomnoMed since 1st September 2016. The Board thanked Mr Smith for his work during his tenure, especially in upgrading the company's capabilities in the Quality & Regulatory Assurance, the Global Production and the Product Development departments.

The Board of SomnoMed has appointed Mr Neil Verdal-Austin as the new Chief Executive of SomnoMed effective 19th November 2018. Mr Verdal-Austin has served as Chief Financial Officer of SomnoMed Limited since October 2008. During this time he also took direct management responsibility for SomnoMed's APAC region, managing the Company's businesses in Australia, New Zealand, Singapore and South Korea successfully over a period of four years to the end of June this year.

"On behalf of our Board I would like to thank Mr Smith for his work over the last two years. We appreciate that this was not an easy period and believe that Mr Smith contributed to the organisation of our company and added important capabilities to a number of departments," said SomnoMed Chairman, Dr Peter Neustadt.

"The change in the leadership of SomnoMed marks a first step in the restructuring of our company and its businesses. The Board is pleased to have been able to appoint a successor for the role of Chief Executive from within the ranks of our senior executives. Mr Verdal-Austin is a most experienced, very dynamic and business focused individual, having worked for medical device companies in South Africa, the UK and in Australia for over 25 years. He has a proven track record in various roles in SomnoMed, with many years of deep involvement in our businesses in Europe, the US and Asia-Pacific. Mr Verdal-Austin very much enjoys the support of our executives and staff around the world. The Board is confident that Mr Verdal-Austin will continue our company's successful growth path it has been on for many years as the global leader in the growing business of treating obstructive sleep apnea patients with custom made oral appliances," commented Dr Neustadt.

Mr Verdal-Austin will address the Annual General Meeting on 27th November 2018 and set out his objectives and priorities for the near and medium term future of SomnoMed.

Contact: Mr. Neil Verdal-Austin, CEO

Ph +61 2 9467 0400 or +61 (0) 406 931 477 - mobile

About SomnoMed

SomnoMed is a public company providing diagnostic and treatment solutions for Sleep-related Breathing Disorders, including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent[®] becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent[®] is the most comfortable and effective design and treatment solution for almost 400,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>